Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Castle Wealth Management LLC

by · The Cerbat Gem

Castle Wealth Management LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,828 shares of the medical research company’s stock after acquiring an additional 147 shares during the quarter. Castle Wealth Management LLC’s holdings in Amgen were worth $1,193,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Capital World Investors lifted its holdings in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. Norges Bank acquired a new stake in Amgen during the 4th quarter worth approximately $1,541,991,000. GAMMA Investing LLC lifted its holdings in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors lifted its holdings in Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Amgen during the 4th quarter worth approximately $401,913,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $296.85 on Thursday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. The firm has a market capitalization of $159.62 billion, a P/E ratio of 27.08, a P/E/G ratio of 2.63 and a beta of 0.49. The company’s fifty day moving average price is $281.75 and its 200 day moving average price is $286.35.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. Amgen’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.96 earnings per share. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. Bank of America increased their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Royal Bank Of Canada reduced their price objective on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Finally, Mizuho raised their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $307.82.

View Our Latest Research Report on Amgen

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.76% of the company’s stock.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).